Annual Drug Patent Expirations for XENLETA
Xenleta is a drug marketed by Nabriva and is included in two NDAs. There are four patents protecting this drug.
Drug patent litigation for XENLETA.
This drug has one hundred and four patent family members in forty-one countries.
The generic ingredient in XENLETA is lefamulin acetate. Additional details are available on the lefamulin acetate profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com